PDCD1 and melanoma: More recently, it has been reported that overall survival (OS) curves show estimated 5-year rates of 34.2% among patients with melanoma, 27.7% among patients with RCC, and 15.6% among patients with NSCLC, indicating that anti-PD-1 treatment is associated with long-term survival in a subset of patients [27].